Fusion Pharm Stock Performance
| FSPM Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Fusion Pharm are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Fusion Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Fusion Pharm is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:200 | Dividend Date 1998-02-27 | Last Split Date 2011-03-01 |
Fusion Pharm Relative Risk vs. Return Landscape
If you would invest 0.01 in Fusion Pharm on November 12, 2025 and sell it today you would earn a total of 0.00 from holding Fusion Pharm or generate 0.0% return on investment over 90 days. Fusion Pharm is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Fusion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fusion Pharm Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fusion Pharm for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fusion Pharm can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 67.01 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures |
Fusion Pharm Fundamentals Growth
Fusion Stock prices reflect investors' perceptions of the future prospects and financial health of Fusion Pharm, and Fusion Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fusion Stock performance.
| Return On Asset | -1.38 | ||||
| Profit Margin | (1.11) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 294.63 K | ||||
| Shares Outstanding | 10.59 M | ||||
| Price To Earning | (0.07) X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 594.4 K | ||||
| Gross Profit | 67.01 K | ||||
| Net Income | (42.08 K) | ||||
| Cash And Equivalents | 1.45 K | ||||
| Total Debt | 1.2 K | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | 239.84 K | ||||
| Earnings Per Share | (0.15) X | ||||
| Total Asset | 4.04 K | ||||
| Retained Earnings | (9.11 K) | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 459 K | ||||
About Fusion Pharm Performance
By examining Fusion Pharm's fundamental ratios, stakeholders can obtain critical insights into Fusion Pharm's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Fusion Pharm is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. The company was founded in 1998 and is based in Commerce City, Colorado. Fusion Pharm operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Fusion Pharm performance evaluation
Checking the ongoing alerts about Fusion Pharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fusion Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 67.01 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures |
- Analyzing Fusion Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fusion Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Fusion Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fusion Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fusion Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fusion Pharm's stock. These opinions can provide insight into Fusion Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Consumer Staples Distribution & Retail sector continue expanding? Could Fusion diversify its offerings? Factors like these will boost the valuation of Fusion Pharm. Market participants price Fusion higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fusion Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fusion Pharm's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.